InSitu Biologics Revenue and Competitors
Estimated Revenue & Valuation
- InSitu Biologics's estimated annual revenue is currently $3.2M per year.
- InSitu Biologics's estimated revenue per employee is $201,000
Employee Data
- InSitu Biologics has 16 Employees.
- InSitu Biologics grew their employee count by 7% last year.
InSitu Biologics's People
Name | Title | Email/Phone |
---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | VP, Clinical Operations and Regulatory Affairs | Reveal Email/Phone |
3 | Director Administration | Reveal Email/Phone |
4 | Chief Science Officer, Cofounder | Reveal Email/Phone |
5 | Chief Operating Officer | Reveal Email/Phone |
InSitu Biologics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $12.9M | 64 | -7% | N/A | N/A |
#2 | $133.5M | 664 | -3% | N/A | N/A |
#3 | $17.1M | 85 | 2% | N/A | N/A |
#4 | $1272.3M | 6330 | -5% | N/A | N/A |
#5 | $67.5M | 336 | 22% | N/A | N/A |
#6 | $60.9M | 303 | N/A | N/A | N/A |
#7 | $1.6M | 8 | 14% | N/A | N/A |
#8 | $82.4M | 410 | 17% | N/A | N/A |
#9 | $21.3M | 106 | 9% | N/A | N/A |
#10 | $104.5M | 520 | 8% | N/A | N/A |
What Is InSitu Biologics?
InSitu Biologics, LLC is an emerging biotech company focusing on development of new and proprietary treatments using its Matrixâ„¢ BioHydrogel. Their lead product, AnestaGelâ„¢, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management. AnestaGelâ„¢ uses a novel approach to delivering sustained-released analgesics into the target tissue via the Matrixâ„¢ BioHydrogel platform, which is a tunable, biocompatible, and pH neutral platform. This allows AnestaGelâ„¢ to provide target site-specific, non-migratory placement, a flexible and high dose drug-load reservoir capacity, and a tunable and predictable pharmacological effect.
keywords:N/AN/A
Total Funding
16
Number of Employees
$3.2M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
InSitu Biologics News
InSitu Biologics: InSitu Biologics is an emerging biotech company focused on the development of a multi-phase prolonged-release drug delivery...
ImmunityBio Provides Updated Status of Biologics License Application (BLA) for ... Non-Muscle Invasive Bladder Cancer Carcinoma in Situ.
Merck Provides Update on FDA Review of Supplemental Biologics License ... Fee Act date of the supplemental biologics license application for...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.4M | 16 | -20% | N/A |
#2 | $1.5M | 17 | N/A | N/A |
#3 | $1.3M | 17 | 0% | N/A |
#4 | $2.9M | 19 | -14% | N/A |
#5 | $4.2M | 22 | 16% | N/A |